sponsored
PatientsVille.com Logo

PatientsVille

Anticoagulant Medical Research Studies

Up-to-date List of Anticoagulant Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Anticoagulant Medical Research Studies

Rank Status Study
1 Not yet recruiting Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events
Conditions: Anticoagulants;   Thromboembolism;   Hemorrhage
Interventions: Other: Measurement of Plasma Concentrations of NOACs;   Genetic: Identification of ABCB1 polymorphisms coding for P-gp
Outcome Measures: Measurement of plasma concentrations of new oral anticoagulant agents;   Identification of polymorphisms of the gene ABCB1 coding for P-gp
2 Unknown  Reversal of the Antithrombotic Action of New Oral Anticoagulants
Conditions: Thrombosis;   Anticoagulant-induced Bleeding;   Anticoagulant Overdosage;   Hemorrhage
Interventions: Drug: Rivaroxaban;   Drug: Dabigatran
Outcome Measures: Modifications in hemostasis parameters.;   Changes observed after in vitro addition of coagulation factor concentrates;   Measure other indirect biomarkers of the activation of the coagulation mechanisms.
3 Recruiting Clinical Decision Rule Validation Study to Predict Low Recurrent Risk in Patients With Unprovoked Venous Thromboembolism
Condition: Idiopathic Venous Thromboembolism
Intervention: Other: Application of the"Men continue and HER DOO2" rule
Outcome Measures: The primary study outcome is the incidence of adjudicated recurrent major VTE at 1 year in patients deemed by the "Men and HER DOO2" CDR to be at low risk of recurrent VTE.;   Any VTE 1 year event rate in low risk patients;   Major bleeding 1 year event rate in un-anticoagulated low risk patients;   Major VTE 1 year event rate in high risk patients who continue anticoagulant therapy;   Major VTE 1 year event rate in high risk patients who discontinue anticoagulant therapy;   Major Bleeding 1 year event rate in high risk patients;   Clinical utility of the rule;   Inter-observer reliability of the clinical decision rule
4 Recruiting Benefits of a Comprehensive Patient Education on Oral Anticoagulant Compared to Conventional Hospital Education
Condition: Cardiac Surgery
Interventions: Behavioral: VKA (antivitamin K) education;   Behavioral: conventional hospital education
Outcome Measure: knowledge test on anticoagulant treatment
5 Recruiting Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
Conditions: Ischemic Stroke;   Patent Foramen Ovale;   Atrial Septal Aneurysm;   Migraine
Interventions: Drug: aspirin;   Drug: Antivitamins K;   Device: Devices for PFO closure
Outcome Measures: stroke(fatal or not);   Disabling stroke;   Ischemic stroke;   Cerebral haemorrhage;   Ischemic stroke, TIA, or systemic embolism;   Death (all causes);   Vascular death;   Moderate to severe bleeding complications;   Procedural or device complications
6 Not yet recruiting Measuring the Incidence of Hospital Readmissions Based on Adverse Drug Events
Conditions: Incidence of Readmissions;   ADE's Due to Anticoagulants
Intervention:
Outcome Measures: incidence of readmissions within one week caused by ADE's due to Anticoagulants;   incidence of readmissions within 30 days caused by ADE's due to Anticoagulants;   incidence of preventable ADE's leading to readmission
7 Unknown  rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets
Condition: Intracerebral Hemorrhage
Interventions: Drug: rFVIIa + (vit K in AO patients);   Drug: FFP or aPCC+ vit K in AO treated patients
Outcome Measures: EFFICACY: change in ICH volume from prior to dosing to 24 hours;   SAFETY: occurrence of clinical adverse events (Thromboembolic events, death);   Difference between groups on the modified Rankin Scale, the Barthel Index (BI), the Extended Glasgow Scale (EGCS), and the National Institute of Health’s Stroke Scale (NIHSS) at one and three month follow up
8 Unknown  Anticoagulant Treatments and Percutaneous Coronary Angioplasty
Condition: Coronary Artery Disease
Interventions: Drug: clopidogrel + aspirin;   Drug: heparin + clopidogrel + aspirin;   Drug: enoxaparin + clopidogrel + aspirin;   Drug: bivalirudin + clopidogrel + aspirin
Outcome Measures: ischaemic events via troponin Ic measurements during 24 hours post procedure;   haemorrhagic events : clinical and biological evaluation
9 Recruiting Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation
Condition: Atrial Fibrillation
Intervention: Other: Educational Intervention
Outcome Measures: Change in proportion of patients taking oral Anticoagulants;   Change in proportion of patients able to continue anticoagulation;   Change in proportion of patients who are not on anticoagulation at baseline and are on anticoagulation;   Death, total;   Stroke, hemorrhagic and non-hemorrhagic;   Major and non-major clinically relevant bleeding
10 Recruiting Sequential Expansion of Comparative Effectiveness of Anticoagulants
Condition: Atrial Fibrillation
Intervention:
Outcome Measures: Stroke;   Major bleeding;   Stroke or systemic embolism;   Systemic embolism;   Ischemic stroke;   Hemorrhagic stroke;   Stroke uncertain classification;   Major intracranial bleeding;   Major extracranial bleeding;   Major gastrointestinal bleeding;   Transient Ischemic Attack;   Myocardial infarction;   Venous Thromboembolism;   Deep vein thrombosis;   Pulmonary Embolism;   Major upper gastrointestinal bleeding;   Major lower gastrointestinal bleeding;   Major urogenital bleeding;   Other major bleeding
11 Recruiting Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
Conditions: Severe Bleeding;   Urgent Surgery
Intervention:
Outcome Measures: Primary Outcome;   Secondary Outcome
12 Not yet recruiting SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial
Condition: Atrial Fibrillation
Intervention: Drug: anticoagulant by physician criteria
Outcome Measures: Stroke;   Systemic embolism;   Subclinical AF rate;   Total mortality;   Cardiovascular mortality;   Myocardial infarction;   Cardiovascular hospitalization;   Bleeding rates
13 Recruiting Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism
Condition: Venous Thromboembolism
Intervention:
Outcome Measures: Major bleeding (International Society on Thrombosis and Haemostasis(ISTH) criteria);   Clinically relevant non-major bleeding (International Society on Thrombosis and Haemostasis(ISTH) criteria);   recurrent venous thromboembolism;   death (all causes)
14 Not yet recruiting Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Condition: Atrial Fibrillation
Interventions: Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Outcome Measures: Acute stroke;   Systemic embolism;   Major Bleeding;   Clinically Relevant Non-Major Bleeding;   All cause death;   Cardioversion Details;   Length of in-hospital stay;   Rhythm status
15 Recruiting Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Condition: Atrial Fibrillation
Intervention: Drug: Non-coumadin Oral Anticoagulant
Outcome Measures: Anticoagulant Utilization;   Bleeding rate
16 Recruiting Efficacy of the Association Mechanical Prophylaxis + Anticoagulant Prophylaxis on Venous Thromboembolism Incidence in Intensive Care Unit (ICU)
Condition: No High Risk of Hemorrhage
Intervention: Device: Intermittent pneumatic compression of the lower limbs
Outcome Measures: combined criterion evaluated at day 6 ± 2 days after randomization: symptomatic venous thromboembolic event, non fatal, objectively confirmed, Death related to PE, Asymptomatic DVT of the lower limbs detected by CUS on day 6.;   Symptomatic thromboembolic events occurred between day 6 and day 90, and total mortality evaluated at 1 month and 3 months.
17 Recruiting SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)
Conditions: Stroke, Acute;   Atrial Fibrillation
Intervention: Other: This is an observational study.
Outcome Measures: Ischemic events;   major bleeding;   modified Rankin Scale;   Modification of anticoagulant medication
18 Not yet recruiting Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs
Conditions: Myeloma;   Venous Thromboembolism
Intervention: Drug: Apixaban
Outcome Measures: Total VTE and VTE-related death. Major and clinically relevant non major bleeding - Major and clinically relevant non major bleeding, defined according to International Society of Thrombosis and haemostasis;   incidence of venous thromboembolic complications;   incidence of major and clinically relevant non major bleeding;   incidence of arterial cardiovascular events
19 Recruiting Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Condition: Hemorrhage
Intervention: Drug: idarucizumab
Outcome Measures: Reversal of anticoagulant effect of dabigatran;   Reversal of Activated Partial Thromboplastin Time (aPTT);   Reversal of Thrombin Time (TT);   Duration of reversal;   Occurrence of major bleeding post-surgery (for Group B only);   Time to cessation of bleeding (for Group A only);   Minimum unbound sum (free) dabigatran;   Reversal of diluted Thrombin Time (dTT) or Ecarin Clotting Time (ECT) after the first infusion and before the start of the second
20 Recruiting Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)
Conditions: Ischemic Stroke;   Intracranial Hemorrhage
Intervention:
Outcome Measures: Rate of hematoma expansion (ICH);   Symptomatic intracerebral haemorrhage after thrombolysis

These studies may lead to new treatments and are adding insight into Anticoagulant etiology and treatment.

A major focus of Anticoagulant research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Anticoagulant